ZOGENIX INC (ZGNX) Stock Price, Forecast & Analysis
USA - NASDAQ:ZGNX - Common Stock
ZGNX Key Statistics, Chart & Performance
The current stock price of ZGNX is 26.68 null. In the past month the price increased by 2.22%. In the past year, price increased by 28.64%.
ZGNX Latest News, Press Relases and Analysis
ZGNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.46 | 967.00B | ||
| JNJ | JOHNSON & JOHNSON | 19.23 | 480.66B | ||
| MRK | MERCK & CO. INC. | 10.54 | 231.94B | ||
| PFE | PFIZER INC | 7.84 | 142.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.14 | 95.28B | ||
| ZTS | ZOETIS INC | 18.74 | 52.65B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.58 | 12.43B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.31 | 10.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.36 | 7.92B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.26B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.10B |
Related stock screener links
About ZGNX
Company Profile
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
Company Info
ZOGENIX INC
5959 Horton St Ste 500
Emeryville CALIFORNIA 94608 US
CEO: Stephen J. Farr
Employees: 218
Phone: 15105508300.0
ZOGENIX INC / ZGNX FAQ
What does ZOGENIX INC do?
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
Can you provide the latest stock price for ZOGENIX INC?
The current stock price of ZGNX is 26.68 null. The price increased by 1.6% in the last trading session.
Does ZGNX stock pay dividends?
ZGNX does not pay a dividend.
How is the ChartMill rating for ZOGENIX INC?
ZGNX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ZOGENIX INC belong to?
ZOGENIX INC (ZGNX) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for ZOGENIX INC?
The Revenue of ZOGENIX INC (ZGNX) is expected to grow by 113.18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ZGNX stock?
ZOGENIX INC (ZGNX) will report earnings on 2022-05-04.
ZGNX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZGNX. When comparing the yearly performance of all stocks, ZGNX is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
ZGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZGNX. Both the profitability and financial health of ZGNX have multiple concerns.
ZGNX Financial Highlights
Over the last trailing twelve months ZGNX reported a non-GAAP Earnings per Share(EPS) of -4.07. The EPS decreased by -5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -278.4% | ||
| ROA | -48.54% | ||
| ROE | N/A | ||
| Debt/Equity | 0.88 |
ZGNX Forecast & Estimates
15 analysts have analysed ZGNX and the average price target is 37.3 null. This implies a price increase of 39.82% is expected in the next year compared to the current price of 26.68.
For the next year, analysts expect an EPS growth of 26.75% and a revenue growth 113.18% for ZGNX